General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Bayer(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Novartis(SIGNIFICANT), Medtronics(MODEST), AstraZeneca Pharmaceuticals(MODEST), Janssen(SIGNIFICANT), Roche(MODEST), Vifor(SIGNIFICANT), LivaNova(MODEST), Novo Nordisk Inc.(MODEST), FIRE1(NONE), Impulse Dynamics(MODEST), Abbott Laboratories(MODEST), Eli Lilly and Company(SIGNIFICANT), CVRx(SIGNIFICANT), Occlutech(MODEST), American Regent(MODEST), Pfizer(MODEST), Applied Therapeutics(MODEST), Cardiac Dimension(MODEST), Cytokinetics(SIGNIFICANT), Edwards(SIGNIFICANT), Element Sciences(SIGNIFICANT), Ely Lilly(SIGNIFICANT), Imbira(MODEST), Innolife(MODEST), Inventiva(SIGNIFICANT), Lexicon(MODEST), Pharmacosmos(MODEST), Sequanna(SIGNIFICANT), SQ Innovation(MODEST), Tricog(MODEST) SPEAKER'S BUREAU: Novartis Corporation(SIGNIFICANT), Janssen Pharmaceuticals, Inc(SIGNIFICANT) EQUITY INTERESTS/STOCK OPTIONS: PharmaIn(NONE) OTHER FINANCIAL BENEFIT: Medscape(SIGNIFICANT), G3 Pharmaceutical(NONE)

View Full Disclosure